Last reviewed · How we verify
Isotretinoin: Reference Medication 2
At a glance
| Generic name | Isotretinoin: Reference Medication 2 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Bioequivalence Study for an Isotretinoin (PHASE1)
- A Study to Determine Bioequivalence of Isotretinoin in Healthy Male Subjects Under Fed Condition (PHASE1)
- Bioequivalence Study of V0057 Versus a Reference Formulation After Single Administration in Healthy Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Isotretinoin: Reference Medication 2 CI brief — competitive landscape report
- Isotretinoin: Reference Medication 2 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI